Breast Cancer Liquid Biopsy Market Growth, Demand and Challenges of the Key Industry Players  2024-2032
                     Global Breast Cancer 
Liquid Biopsy Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
Acco r d ing  t o  t he  l a t es t  r ep o r t  by  I M ARC  G r oup ,  t i t l ed  " Brea s t  Ca ncer  L i q u i d  
B i o psy  M ark e t :  G l o ba l  I ndu st ry  T ren ds ,  S hare ,  S i z e ,  G row t h ,  O pp or t un i t y  and  
For ec as t  20 24 - 2 032 , "  t he  g loba l  b r eas t  cance r  l i qu id  b iopsy  m ar k e t  s i ze  r eac hed  
US$  130 . 4  M i l l i o n  i n  2 023 .
Report Br ea s t  can ce r  l i qu id  b iopsy  r e f e r s  t o  a  non - inva s i ve  m ed ic a l  p r oce ss  t ha t  use s  b lood  as  a  sa m p le  f o r  t h e  r e cogn i t i on  o f  t um or  m ar k e r s .  I t  he lps  i n  eva lu a t i ng  t he  
p r og r ess io n  o f  b r e as t  ca nce r  d i sease  a nd  de t ec t s  E p ide r m a l  G r o wt h  Fac t o r  R ecep t o r  
Highlight and ( EG FR)  gen e  m u t a t i ons  t ha t  ass i s t  h ea l t h  p r o f ess io na l s  i n  choo s ing  t he  bes t  cou r se  
o f  t r ea t m en t  a t  t he  a pp r o p r ia t e  t im e .  
Som e o f  t h e  m os t  com m on l y  u sed  b iom ar ke r s  i nc lude  ex t r ace l l u l a r  ves i c le s ,  
Description c i r cu la t i ng  t um o r  ce l l s  ( C TC) ,  c i r c u la t in g  t um o r  D NA,  and  o t he r s .  I n  r ece n t  yea r s ,  
b r ea s t  cance r  l i qu id  b iops y  h as  ga ined  t r ac t i on  as  i t  o f f e r s  num er ous  adv an t age s ,  
such  as  t he  cha r ac t e r i za t i on  o f  ne w les io ns ,  m in im a l  i nvas i vene ss ,  d r ug  a nd  
t he r apeu t i c  t a r ge t  i den t i f i ca t i ons  f o r  c ance r  t r e a t m en t .
Reque st  f o r  a  P DF  s ampl e  o f  t h i s  repor t :  
h t t p s : / / www. im ar c g r ou p . com / b r e as t - c ance r - l i qu id - b iop sy - m ar k e t / r e ques t sam p le
Report Description
G lo b a l  B r e a s t  C a n c e r  L iq u i d  B io p s y  M a r k e t  T r e n d s :
O n e  o f  t h e  p r i m a r y  f a c t o r s  d r i v i n g  t h e  m a r k e t  i s  t h e  i n c r e a s i n g  n u m b e r  o f  i n d i v i d u a l s  d i a g n o s e d  w i t h  b r e a s t  c a n c e r .  A d d i t i o n a l l y ,  
b r e a s t  c a n c e r  l i q u i d  b i o p s y  o f f e r s  mu l t i p l e  b e n e f i t s ,  s u c h  a s  q u i c k e r  r e s u l t s ,  m i n i m a l  h e a l t h  r i s k ,  l o w e r  c o s t ,  n o n - i n v a s i v e n e s s ,  
a n d  o t h e r s ,  t h e r e b y  c r e a t i n g  a  p o s i t i v e  m a r k e t  o u t l o o k .  O th e r  t h a n  t h i s ,  t h e  s u r g i n g  d e m a n d  f o r  p r e - s c r e e n i n g  p r o g r a m s  f o r  b r e a s t  
c a n c e r  d e te c t i o n ,  a l o n g  w i t h  e a s y  a c c e s s i b i l i t y  a n d  e x t e n s i v e  u t i l i z a t i o n  o f  p o l y m e r a s e  c h a i n  r e a c t i o n  ( P C R )  a n d  n e x t - g e n e r a t i o n  
s e q u e n c i n g  ( N G S )  a m o n g  c l i n i c a l ,  i s  p o s i t i v e l y  i n f l u e n c i n g  t h e  m a r k e t  g r o w th .  
B e s i d e s  t h i s ,  n u m e r o u s  g l o b a l  o r g a n i z a t i o n s  a r e  c o n d u c t i n g  a w a r e n e s s  c a m p a i g n s  i n  o r d e r  t o  e d u c a t e  i n d i v i d u a l s  a b o u t  b r e a s t  
h e a l t h  a n d  c a n c e r  d i a g n o s t i c  m e a s u r e s .  I n  l i n e  w i t h  t h i s ,  g o v e r n m e n t s  o f  n u m e r o u s  n a t i o n s  a r e  o f f e r i n g  r e i m b u r s e m e n t  p o l i c i e s  
f o r  b r e a s t  c a n c e r  b i o p s y  a n d  o t h e r  r e l a t e d  m e d i c a l  p r o c e d u r e s ,  c o n s e q u e n t l y  p r o p e l l i n g  m a r k e t  g r o w t h .  F u r t h e r m o r e ,  k e y  p l a y e r s  
a r e  e x t e n s i v e l y  i n v e s t i n g  i n  t h e  i n t r o d u c t i o n  o f  a d v a n c e d  b i o p s y  t e c h n i q u e s  t h a t  i m p r o v e  s e v e r a l  a s p e c t s  o f  b r e a s t  c a n c e r  
m a n a g e m e n t ,  i n c l u d i n g  e a r l y  d i a g n o s i s  o f  r e l a p s e ,  e f f i c i e n t  l o n g i t u d i n a l  m o n i t o r i n g  o f  d i s e a s e s  p r o g r e s s  a n d  r e s p o n s e  t o  
t r e a tm e n t ,  a n d  o t h e r s .
L o o k in g  f o r w a r d ,  I M A R C  G r o u p  e x p e c t s  t h e  m a r k e t  v a lu e  t o  r e a c h  U S $  4 9 7 .2  M i l l i o n  b y  2 0 3 2 ,  e x p a n d i n g  a t  a  C A G R  o f  1 5 .5 %  
d u r in g  t h e  f o r e c a s t  p e r i o d  ( 2 0 2 4 - 2 0 3 2 ) .
V ie w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w w w . i m a r c g r o u p . c o m / b r e a s t - c a n c e r - l i q u i d - b i o p s y - m a r k e t
Breakup by Product Services:
• Reagent Kits
• Instruments
• Services
 
Breakup by Circulating Biomarker:
Report • Circulat ing Tumor Cel ls (CTCs)
• Cel l -Free DNA (cfDNA)
Segmentation
• Extracel lular Vesicles (EVs)
• Others
Breakup by End User:
• Reference Laboratories
• Hospitals and Physician Laboratories
• Others
Breakup by Region:
• North America
Report • Asia-Pacifi c
• Europe
Segmentation • Latin America
• Middle East and Afr ica
• Biocept Inc.
• Bio-Rad Laboratories Inc.
• F. Hoff mann-La Roche AG
Competitive • Fluxion Biosciences Inc.
Landscape • Guardant Health Inc.
• I l lumina Inc.
with Key 
• Menarini  Si l icon Biosystems (The Menarini  
Players Group)
• NeoGenomics Laboratories Inc.
• Qiagen
• Sysmex Europe SE (Sysmex Corporat ion).
What was the size of the global breast cancer liquid 
biopsy market in 2023?
What is the expected growth rate of the global 
breast cancer liquid biopsy market during 2024-
2032?
Key What has been the impact of COVID-19 on the 
global breast cancer liquid biopsy market?
Questions 
Answered in What are the key factors driving the global breast cancer liquid biopsy market?
the Report
What is the breakup of the global breast cancer 
liquid biopsy market based on the product services?
What are the key regions in the global breast 
cancer liquid biopsy market?
Who are the key players/companies in the global 
breast cancer liquid biopsy market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  B r e a s t  C a n c e r  L i q u i d  B i o p s y  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  P r o d u c t  S e r v i c e s
    6 . 1     R e a g e n t  K i t s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     I n s t r u m e n t s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     S e r v i c e s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  C i r c u l a t i n g  B i o m a r k e r
       
    7 . 1     C i r c u l a t i n g  T u m o r  C e l l s  ( C T C s )
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     C e l l - F r e e  D N A  ( c f D N A )
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     E x t r a c e l l u l a r  V e s i c l e s  ( E V s )
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     O th e r s
Table of         7 . 4 . 1  M a r k e t  T r e n d s        7 . 4 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  E n d  U s e r
    8 . 1     R e fe r e n c e  L a b o r a t o r i e s  
Contents         8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     H o s p i t a l s  a n d  P h y s i c i a n  L a b o r a to r i e s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     O th e r s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  R e g i o n
    9 . 1     N o r t h  A m e r i c a
        9 . 1 . 1  U n i t e d  S t a te s
           9 . 1 . 1 . 1  M a r k e t  T r e n d s
           9 . 1 . 1 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t io n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/breas t -cancer- l i qu id -b iopsy-ma
rket / toc
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: